[Clinical trial by perexiline maleate in treatment of angina pectoris (author's transl)].
A controlled double blind clinical trial has been conducted in 16 patients with "angina pectoris" in order to investigate the effect of Perexiline maleate as compared with prenilamine. Perexiline at the dose of 400 mg/die and prenilamine at the dose of 120 mg/die have been administered over a period of 4 weeks each. Between these periods placebo has been administered for two weeks. The number of attacks of angina and the number of tablets of nitroglycerine used per week by the patient during each period has been used for the evaluation. Furthermore ECG at rest and after exercise has been performed every two weeks. Our results statistically evaluated show a definite antianginal effect of Perexiline. According to our experience Perexiline should be considered the drug of choise in the treatment of angina complicated by bradicardia, left ventricular failure, bronchospasm, and in angina unresponsive to other drugs.
D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004341:Drug Evaluation; D004562:Electrocardiography; D006261:Headache / Q000139:chemically induced; D006801:Humans; D010480:Perhexiline / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D011299:Prenylamine / Q000627:therapeutic use; D011674:Pulse / Q000187:drug effects; D012893:Sleep Wake Disorders / Q000139:chemically induced
D010880:Piperidines; D011299:Prenylamine; D010480:Perhexiline
Esperienza clinica con perexiline maleato nel trattamento dell'angina pectoris